The recent development of SM-induced pluripotent stem cells (iPSCs) positive for KIT D816V and other concurrent mutations [180], which accurately reflect the genetic background of SM patients’ multi-mutated pathological cells, may become a powerful tool to dissect the impact of these mutations on the aetiopathogenic mechanisms involved in disease progression [181]. Here, KIT is linked to systemic mastocytosis.